Condition: Systemic Sclerosis (SSc) · Dermatomyositis · Mixed Connective Tissue Disease (MCTD) · Sponsor: Robyn T. Domsic, MD, MPH
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
This description comes directly from the study's public registry record.
Maureen M Laffoon, BS · 412-648-7874 · laffoonm@pitt.edu
Always discuss trial participation with your own doctor first.
| UPMC Arthritis and Autoimmunity Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06672822